Trump's Reset Can Give Birth To America's Greatest Era Yet
A 90-Year cycle may end soon, creating real wealth for early adopters
In 1933, Executive Order 6102 forced everyday Americans to hand over their gold at a fixed rate.
Everyday citizens lost a sizable amount of their hard earned wealth at the stroke of FDR's pen.
Now, 92 years later, President Trump has focused his energy on making things right.
His next move has the power to trigger a financial reset that could shift trillions of dollars into the hands of the people.
A provision buried in the U.S. Code Title 31, Section 5117 allows the U.S. Treasury to revalue America's gold reserves from an outdated $42 per ounce to today's market price.
That's a 72x increase!
If activated, it could
- Reinforce America's financial dominance
- Reignite trust in value-backed money, making the dollar valuable again
- Spark a modern day gold rush once the public understand their choices
And the best part…
Over 60 Million Americans are eligible to become a first wave benefactor in Trump's Gold Reset.
However, only those who download a copy of our 2025 Wealth Protection Guide will know the simple steps needed to take part in this historic wealth reset.
Claim Your FREE Guide Now and discover how to position yourself for this golden opportunity.
Request Your FREE WEALTH PROTECTION GUIDE Today!
How Royalty Pharma Prints Cash Without Biotech's Biggest Risks
Written by Jeffrey Neal Johnson. Published 10/31/2025.
Key Points
- The company's unique business model offers investors diversified exposure to a portfolio of successful, revenue-generating biopharmaceutical products.
- Recent strategic acquisitions of royalties on promising new therapies demonstrate the company’s ability to identify and secure future blockbuster revenue streams.
- Strong cash flow generation supports continued investment in new royalties and a commitment to returning capital to shareholders.
Investing in biotechnology often feels like navigating a minefield. A single failed clinical trial can decimate a stock; a blockbuster approval can generate spectacular returns. That extreme volatility deters many investors. But an alternative model lets investors participate in the industry's upside while mitigating its most significant risks.
Royalty Pharma plc (NASDAQ: RPRX) has perfected this approach. Operating as a strategic financier rather than a traditional drug developer, the company has delivered year-to-date stock appreciation of more than 42%.
The Recession Already Started, Are You Prepared? (Ad)
Global central banks are stockpiling gold. Billionaires are hedging with precious metals. And thousands of Americans are shifting savings out of traditional accounts to protect what they’ve earned.
If you’re concerned about inflation, rising debt, or a falling dollar, this free Wealth Protection Kit includes three timely reports to help you prepare for what’s coming next.
This performance is supported by recent activity, including deploying nearly $1.3 billion across two major deals and raising an additional $2 billion in capital to fuel future growth — reinforcing its position as a lower-risk way to invest in the future of medicine.
How Royalty Pharma Prints Money From Medicine
Royalty Pharma's business model is straightforward. A biopharmaceutical royalty is a contractual right to a percentage of a drug's top-line sales. The company provides large, upfront cash payments to drug developers, academic institutions, and other innovators in exchange for the rights to those future royalties.
This structure creates clear benefits for all parties:
- For partners: Immediate, non-dilutive funding for critical activities such as late-stage trials or commercial launches.
- For Royalty Pharma: Long-term, cash-generating assets tied to the performance of de-risked medicines.
For investors, the key is diversification. Royalty Pharma's portfolio includes more than 35 revenue-generating therapies across major areas such as oncology, rare diseases, and immunology. That breadth spreads risk, so the underperformance of any single product is unlikely to derail the company’s overall cash flow. In effect, it converts biotech’s inherent unpredictability into a more stable, forecastable business.
Deploying Capital, Delivering Growth
Royalty Pharma's recent moves show a disciplined strategy: raise capital efficiently, deploy it into high-quality assets, and return proceeds to shareholders.
A Fresh $2 Billion for New Opportunities
In September, the company priced a $2 billion offering of senior unsecured notes with maturities extending to 2055. The successful capital raise highlights its strong access to debt markets and provides the dry powder needed to execute large-scale acquisitions from a position of financial strength.
Betting on a Blockbuster Cancer Drug
In August, Royalty Pharma acquired a royalty interest in Amgen's (NASDAQ: AMGN) cancer therapy, IMDELLTRA, for up to $950 million. IMDELLTRA is a first-in-class treatment for small-cell lung cancer, an aggressive disease with a poor prognosis. The drug is already FDA-approved and on the market, generating $215 million in sales in the first half of 2025. The deal secures a long-duration royalty stream expected to continue through at least 2038 on a commercial-stage asset with analyst-projected blockbuster potential.
Funding Innovation With Built-in Protection
Also in September, Royalty Pharma partnered with Zenas BioPharma (NASDAQ: ZBIO), committing up to $300 million for a 5.5% royalty on its autoimmune candidate, Obexelimab. The deal is structured to mitigate risk by tying payments to clinical and regulatory milestones. That structure showed early promise when Zenas announced positive Phase 2 data in multiple sclerosis on Oct. 27, 2025, validating the drug's franchise potential and highlighting management’s ability to identify promising assets.
Sharing the Success With Investors
Robust cash flow from this model enables Royalty Pharma to fund growth and return capital to shareholders. The company has a $3 billion share repurchase program and bought back $1 billion of stock in the first half of 2025 alone. It also maintains a consistent and growing dividend, which increased 4.8% in January 2025 and was reaffirmed at $0.22 per share for the fourth quarter.
A Bullish Case With a Dose of Realism
The outlook for Royalty Pharma remains favorable. Wall Street analysts hold a consensus Buy rating on the stock, with an average price target of $46 and a high-end target of $54, implying meaningful upside from current levels. A near-term catalyst will be the company's Q3 2025 financial results, scheduled for release on Nov. 5.
That said, the model is not risk-free. Investors should monitor the ongoing royalty dispute with Vertex Pharmaceuticals (NASDAQ: VRTX) over the drug Alyftrek. Still, this appears to be a manageable, single-product issue given Royalty Pharma’s diversified portfolio of more than 35 commercial products, which reduces reliance on any one revenue stream.
For investors seeking a disciplined, financially robust way to gain exposure to the biopharmaceutical sector, Royalty Pharma’s recent strategic execution demonstrates a company operating near the top of its field.
